Urban Supreme System

In the email Li Changhua sent to Su Zhe, he listed many pharmaceutical companies.

Although these are all pharmaceutical companies that can be transferred intentionally, after actual screening, there are not many pharmaceutical companies that can meet Su Zhe's conditions.

The smallest pharmaceutical company among them is almost the same size as Changhua Pharmaceutical Factory, and its productivity is slightly smaller than that of Changhua Pharmaceutical Factory.

This pharmaceutical company occupies an area of ​​4.8 hectares in Shenzhou High-tech Zone, including the construction of solid preparation factories, raw material and finished product warehouses and company office buildings. The total construction area is 21,000 square meters, with an annual output of 1.8 billion capsules and 400 million bags of granules. , 900 million tablets.

If acquired, after integration, the output of Changhua Pharmaceutical Factory can be doubled.

But Su Zhe eliminated them directly, and the output could only be doubled, which was of little significance to Changhua Pharmaceutical Factory.

Although it is necessary to solve the production problem of Changhua Pharmaceutical once and for all, it is impossible for Changhua Pharmaceutical.

But under Su Zhe's conditions, at least after acquiring a pharmaceutical company, he could no longer worry about Changhua Pharmaceutical's productivity issues in a short period of time.

For pharmaceutical companies of this size, there is no need to consider it. I believe that even after the acquisition, according to the current development speed of Changhua Pharmaceutical, such productivity will soon reach its peak.

It also takes time for Changhua Pharmaceutical to integrate the pharmaceutical companies it acquired, and Su Zhe didn't want to waste time on it.

Therefore, Su Zhe would never consider a pharmaceutical company of this size.

Of course, for pharmaceutical companies with low output, the acquisition price is also relatively low. And a pharmaceutical company like this one. The estimated purchase price is 320 million.

Except for this one pharmaceutical company. There are several pharmaceutical companies, none of which are large in scale, and the estimated purchase prices are between 300 million and 800 million.

But these pharmaceutical companies were not among Su Zhe's considerations, so he skipped these pharmaceutical companies first.

The estimated purchase prices of the next several pharmaceutical companies are all over 1 billion.

A pharmaceutical company of this size. This is what Su Zhe wants. Therefore, Su Zhe started to choose directly from here.

Finally, after Su Zhe carefully checked the information, one of them, named Xinjing Pharmaceutical Company,

Make him most satisfied.

However, this pharmaceutical company is the largest among them, and its acquisition price is also the highest.

This Xinjing pharmaceutical company was established not long ago. At that time, the founder of this Xinjing pharmaceutical company was very ambitious. Want to build a first-class pharmaceutical company.

Therefore, when Xinjing Pharmaceutical Company built its factory, it invested a lot of money. The imported production line is still regarded as an internationally advanced and domestic first-class modern production line, with more than 1,000 employees.

This Xinjing pharmaceutical company mainly produces eight categories of preparations, including tablets, capsules, granules, water injections, powder injections, freeze-dried powder injections, oral liquids, and soft capsules, as well as erythromycin ethylsuccinate, erythromycin, and tetracycline hydrochloride. , erythromycin phospho, calcium dobesilate, urapidil, isosodium, and leucine A.

This Xinjing pharmaceutical company covers an area of ​​440,000 square meters and a construction area of ​​180,000 square meters. Its output is several times that of Changhua Pharmaceutical.

It can annually produce 12 billion tablets, 8 billion capsules, 140 million packets of granules, 50 million water injections, 20 million powder injections, and 20 million freeze-dried powder injections.

However, it is a pity that this Xinjing pharmaceutical company has been lacking its own flagship products since its establishment. Its independent products have never been well-known and have been unable to open up the pharmaceutical market.

As a result, this Xinjing pharmaceutical company has been unable to make ends meet.

In order to maintain operations, Xinjing pharmaceutical companies currently focus on OEM, but the output of independent products is very low.

The situation of Xinjing Pharmaceutical Company is almost the same as that of Changhua Pharmaceutical before Su Zhe took a stake in it. They are both heavily in debt and facing bankruptcy or acquisition.

The difference is that the scale of this Xinjing Pharmaceutical Company is much larger than that of Changhua Pharmaceutical, and its liabilities are also higher.

It is currently estimated that Changhua Pharmaceutical will need to pay a huge sum of money to acquire Xinjing Pharmaceutical Company.

In fact, Li Changhua and Liu Xiong's choices were the same as Su Zhe's. Among the pharmaceutical companies listed by the two of them, there were special notes for Su Zhe to carefully consider three of them.

The Xinjing Pharmaceutical Company that Su Zhe is currently interested in is one of them, and they are also optimistic about Xinjing Pharmaceutical Company.

What excites Su Zhe and the others the most is that Xinjing Pharmaceutical Company also owns 50,000 acres of land, a Chinese herbal medicine planting base. This is one of the reasons why they are interested in this pharmaceutical company.

Because in this Chinese medicinal material planting base, most of the Chinese medicinal materials grown are needed for the production of medicines such as Thalysin.

Therefore, if Changhua Pharmaceutical acquires Xinjing Pharmaceutical Company and owns this 50,000-acre Chinese medicinal material planting base, then Changhua Pharmaceutical will not have to worry about being restricted in the production of raw materials.

Liu Xiong had previously proposed building his own Chinese herbal medicine planting base because he was mainly worried that Changhua Pharmaceutical would be subject to other controls on raw materials.

If Changhua Pharmaceutical had its own Chinese herbal medicine planting base, it would not have to worry about this problem.

I didn't expect that Xinjing Pharmaceutical Company also has its own Chinese medicinal material planting base, with a scale of 50,000 acres.

It can be seen that Xinjing Pharmaceutical Company at that time had the determination to develop into a first-class pharmaceutical company, otherwise it would not have built an entire production chain.

It's just that Xinjing Pharmaceutical Company has had bad luck and has not developed any beneficial products. Coupled with management errors, it faced this situation.

Xinjing Pharmaceutical Company, which has such conditions, will become the best choice for Su Zhe and others.

Su Zhe thought that Li Changhua and Liu Xiong should be like him. It was also because of this that they chose Xinjing Pharmaceutical Company.

However, it is not easy to acquire Xinjing Pharmaceutical Company.

Although Xinjing Pharmaceutical Company is now interested in transferring it, its selling price is not low.

Based on the current scale of Xinjing Pharmaceutical Company, its own Chinese herbal medicine planting base, and including the assumption of debts, etc., preliminary estimates suggest that Changhua Pharmaceutical will need to pay 2.2 billion for this.

Although the sales of the three drugs currently launched by Changhua Pharmaceutical Factory are very good, after all, the launch time of these three drugs is only a few months at most.

Moreover, because medicines such as Thalysin are priced too low, the actual profit is not high, and the sales time is not long.

Therefore, the funds currently accumulated by Changhua Pharmaceutical Factory are actually not very sufficient. (To be continued...)

...

... ()